<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230715058780N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-28</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of efficacy and side effects of combination Nesdonal - Fentanyl - Midazolam with  Etomidate - Fentanyl - Midazolam for sedation of patients undergoing cataract surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of efficacy and side effects of combination Nesdonal - Fentanyl - Midazolam with Etomidate - Fentanyl - Midazolam for sedation of patients undergoing cataract surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: At the beginning of each day, samples are selected based on the inclusion criteria and after informed consent, random allocation is done based on the file number by random allocation software. People are divided into two groups A and B, for the purpose of blinding, only one reliable person, other than the researcher and data collector, is aware of the type of intervention, then each group is printed in two separate but similar lists. The type of sedation and the people in each group are confirmed by respected anesthesia experts. The data collector only knows the patients by their file number and has no knowledge of the type of intervention. Also, these data are still available to the data analyst in two groups, nicknamed A and B, and the type of intervention remains with the designated person until the end of the analysis, Blinding description: The three-way blinding of the study in terms of: 1) the patient does not know the type of injectable drugs. 2) The data collector has no knowledge of injectable drugs. 3) The data analyst has no knowledge of which group the data belongs to. For the purpose of blinding, similar syringes are used without a specific color and name and are covered with aluminum foil, and after collecting the data until the end of the statistical analysis, Randomly, one group is called A and the other B.</study_design>
      <phase>3</phase>
      <hc_freetext>Cataract surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: The FIRST group is first injected with midazolam and fentanyl intravenous bolus with the following dose: fentanyl 1 Microg/Kg, midazolam 0.02 Mg/Kg, then after 3 minutes intravenous bolus Nesdonal is injected with the following dose: 3mg/kg. Intervention 2: Intervention group :The second group is first injected with intravenous midazolam and fentanyl bolus with the following dose: midazolam 0.02 mg/Kg, fentanyl 1 Microg/Kg, then after 3 minutes, Etomidate is injected as an infusion: 0.03mg/kg/h.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is We have not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mitra Jabal Ameli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Medicine., Isfahan University of Medical Sciences and Health Services., Hazar Jarib St</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3620 1992</telephone>
        <email>jabalameli@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mitra Jabal Ameli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Medicine., Isfahan University of Medical Sciences and Health Services., Hazar Jarib St</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3620 1992</telephone>
        <email>jabalameli@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Cataract surgery candidates for emulsification method
Having (ASA) between 1 and 3
Age between 18 and 70 years
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Parkinson's
Occurrence of acute cardiac ischemia in the last three months
Having a history of narcotic drugs use
Having a history of allergy to anesthetics
Pregnancy
Weighing more than one hundred kilograms
Baseline blood pressure greater than 180/110
Dyspenea
Psychosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H25.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Age-related incipient cataract</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: The FIRST group is first injected with midazolam and fentanyl intravenous bolus with the following dose: fentanyl 1 Microg/Kg, midazolam 0.02 Mg/Kg, then after 3 minutes intravenous bolus Nesdonal is injected with the following dose: 3mg/kg</i_keyword>
      <i_keyword>Intervention group :The second group is first injected with intravenous midazolam and fentanyl bolus with the following dose: midazolam 0.02 mg/Kg, fentanyl 1 Microg/Kg, then after 3 minutes, Etomidate is injected as an infusion: 0.03mg/kg/h</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure. Timepoint: before receiving the drugs, after receiving, 5, 10, 20 minutes after the start of surgery and during recovery, first immediately and then every 15 minutes until leaving the recovery. Method of measurement: Operating room monitoring device.</prim_outcome>
      <prim_outcome>Respiratory rate per minute. Timepoint: before receiving the drugs, after receiving, 5, 10, 20 minutes after the start of surgery and during recovery, first immediately and then every 15 minutes until leaving the recovery. Method of measurement: Operating room monitoring device.</prim_outcome>
      <prim_outcome>Heart rate per minute. Timepoint: before receiving the drugs, after receiving, 5, 10, 20 minutes after the start of surgery and during recovery, first immediately and then every 15 minutes until leaving the recovery. Method of measurement: Operating room monitoring device.</prim_outcome>
      <prim_outcome>Blood oxygen saturation percentage. Timepoint: before receiving the drugs, after receiving, 5, 10, 20 minutes after the start of surgery and during recovery, first immediately and then every 15 minutes until leaving the recovery. Method of measurement: Operating room monitoring device.</prim_outcome>
      <prim_outcome>Determining and comparing the average length of stay in recovery Community Verified icon. Timepoint: After transfer to recovery until the end. Method of measurement: timer.</prim_outcome>
      <prim_outcome>Determining and comparing the frequency of sedation. Timepoint: At the time of receiving the drugs and 5, 10, 20 minutes after the start of the surgery Community Verified icon. Method of measurement: Determining sedation with the Ramsay-Sedation-Scale.</prim_outcome>
      <prim_outcome>Determining and comparing the frequency of surgeon satisfaction Community Verified icon. Timepoint: End of surgery. Method of measurement: CHECK LIST.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Determining and comparing the frequency of intramuscular metoclopramide consumption in recovery. Timepoint: After exiting recovery. Method of measurement: Determining nausea based on Baxter Retching Faces and metoclopromide injection in scores higher than 6 and counting doses.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-01</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Research and Technology Vice-Chancellorm., Building No. 4., Isfahan University of Medical Sciences and Health Care Services., Hazar Jarib St esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
